Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2017-001819-36Phase 3Completed
Phase 3, randomised, double-blind trial of Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by VBI Vaccines Inc. Primary endpoint: Seroprotection rate at Day 196. Started Dec 2017; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2017-001819-36.